The main brands of lisinopril include Zestoretic, Prinivil, Zestril, among others. Zestoretic is a combination medication containing lisinopril, an ACE inhibitor, and hydrochlorothiazide, a thiazide diuretic. It is used to treat conditions such as hypertension, heart failure, heart attacks, strokes, diabetic kidney disease, among others. It is available in various forms such as tablets and liquid, and is prescribed to different populations including children and adults. These medications are used by various end-users such as hospitals, specialty clinics, and others.
The lisinopril market research report is one of a series of new reports that provides lisinopril market statistics, including lisinopril industry global market size, regional shares, competitors with a lisinopril market share, detailed lisinopril market segments, market trends, and opportunities, and any further data you may need to thrive in the lisinopril industry. This lisinopril market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The lisinopril market size has grown strongly in recent years. It will grow from $1.66 billion in 2023 to $1.76 billion in 2024 at a compound annual growth rate (CAGR) of 6%. The growth during the historic period can be attributed to increased accessibility, lifestyle changes, expanded screening programs, greater availability of generic lisinopril, and improved patient adherence.
The lisinopril market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to the rising prevalence of hypertension and cardiovascular diseases, the availability of generic versions and their cost-effectiveness, increased awareness and early diagnosis, the growing demand for effective treatments, and an aging population. Major trends during this period include innovations in drug delivery, the need for enhanced and patient-centric drug delivery approaches, the demand for cost-effective solutions, and the demand for effective treatments for both heart failure and diabetic kidney disease.
The increasing prevalence of cardiovascular diseases is anticipated to drive the growth of the lisinopril market in the coming years. Cardiovascular diseases (CVDs) include a variety of disorders affecting the heart and blood vessels. Several factors contribute to the rising prevalence of CVDs, such as population growth, aging, risk factors, and the lack of effective prevention and treatment strategies. Lisinopril helps manage cardiovascular diseases mainly by lowering blood pressure and reducing the strain on the heart and kidneys. It works by inhibiting the production of angiotensin II, which facilitates blood vessel dilation, reduces blood volume, and protects organs from damage. For example, according to the Centers for Disease Control and Prevention, the prevalence of coronary heart disease among adults aged 18 and over increased slightly from 4.6% in 2020 to 4.9% in 2021. Thus, the rising prevalence of cardiovascular diseases is driving the growth of the lisinopril market.
The growing prevalence of hypertension is expected to boost the lisinopril market. Hypertension, or high blood pressure, is a condition where the force of blood against artery walls is consistently too high. Factors such as an unhealthy diet, sedentary lifestyle, aging population, and long-term stress contribute to the increasing prevalence of hypertension. Lisinopril effectively manages hypertension by blocking the formation of angiotensin II, leading to blood vessel relaxation, reduced blood volume, and lower blood pressure. For instance, the World Health Organization reported in March 2023 that around 1.28 billion adults aged 30-79 worldwide had hypertension. Therefore, the increasing prevalence of hypertension is driving the lisinopril market.
In January 2024, Sun Pharmaceutical Industries Limited, an Indian pharmaceutical company, acquired Taro Pharmaceutical Industries Ltd for $347.73 million. This acquisition allows Sun Pharma to expand its portfolio by incorporating Taro's expertise in generic and specialty medicines, active pharmaceutical ingredients (APIs), and over-the-counter products. Taro Pharmaceutical Industries Ltd, a US-based company, offers lisinopril.
Major companies operating in the lisinopril market are Merck & Co. Inc., Pfizer Inc., AbbVie Inc., AstraZeneca Plc, Vitaris Inc., Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc., Hetero Ltd., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd., Cipla Inc., Hikma Pharmaceutical Plc, Apotex Inc., Amneal Pharmaceutical Inc., Lupin Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Metrochem API Private Limited, Calyx Chemicals & Pharmaceuticals Limited, Farmhispania Group, Zydus Cadila Healthcare Ltd., Qingdao Qingmei Biotech Co. Ltd., LGM Pharma LLC, Amara Labs Pvt., Sms Lifesciences.
North America was the largest region in the lisinopril market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lisinopril market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the lisinopril market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The lisinopril market consists of sales of prinivil, qbrelis, zestoretic, zestril and apo-lisinopril. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Lisinopril Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on lisinopril market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for lisinopril ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lisinopril market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Brand: Zestoretic; Prinivil; Zestril; Other Brands2) By Disease: Hypertension; Heart Failure; Heart Attack; Strokes; Diabetic Kidney Disease; Other Diseases
3) By Dosage: Tablet; Liquid; Other Dosages
4) By Population Type: Children; Adults
5) By End-Users: Hospitals; Specialty Clinics; Other End-Users
Key Companies Mentioned: Merck & Co. Inc.; Pfizer Inc.; AbbVie Inc.; AstraZeneca Plc; Vitaris Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck & Co. Inc.
- Pfizer Inc.
- AbbVie Inc.
- AstraZeneca Plc
- Vitaris Inc.
- Teva Pharmaceutical Industries Limited
- Bausch Health Companies Inc.
- Hetero Ltd.
- Sun Pharmaceutical Industries Limited
- Aurobindo Pharma Ltd.
- Cipla Inc.
- Hikma Pharmaceutical Plc
- Apotex Inc.
- Amneal Pharmaceutical Inc.
- Lupin Ltd.
- Zhejiang Huahai Pharmaceutical Co. Ltd.
- Metrochem API Private Limited
- Calyx Chemicals & Pharmaceuticals Limited
- Farmhispania Group
- Zydus Cadila Healthcare Ltd.
- Qingdao Qingmei Biotech Co. Ltd.
- LGM Pharma LLC
- Amara Labs Pvt.
- Sms Lifesciences
Methodology
LOADING...